Effect of omega 3 on cardiac necrosis biomarkers, TnI and CK-MB
Not Applicable
- Conditions
- heart disease.Atherosclerosis
- Registration Number
- IRCT2015040920441N2
- Lead Sponsor
- Shiraz University of Medical Sciences, International branch
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 80
Inclusion Criteria
Informed consent form; NSTE-ACS candidate for elective PCI; treatment with ASA at least 5 days before PCI; CKD patients (GFR ? 60 ml/min) Exclusion criteria: CABG during last 3 months; treatment with glycoprotein IIb/IIIa inhibitors during PCI; treatment with bivalirudine during PCI; sensitivity or tolerance to ASA or Clopidogrel; unsatisfactory PCI; sever active bleeding; sever adverse effects to drugs
Exclusion Criteria
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Creatine kinase-MB. Timepoint: 24 hours after PCI. Method of measurement: ELISA.;Troponin I. Timepoint: 24 hours after PCI. Method of measurement: ELISA.
- Secondary Outcome Measures
Name Time Method Major Adverse Cardiac Effect (MACE). Timepoint: 30 days after PCI. Method of measurement: Following patients by phone.